Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07203196 · ClinicalTrials.gov registry record · NA

Circadian Health Regulation and Optimization for Rejuvenation Outcomes

A NA study of Time-restricted Eating and Circadian Dysregulation, sponsored by Salk Institute for Biological Studies.

Active
Registry status
NA
Development phase
16
Enrollment target
1
Study location

NCT07203196: Active NA study of Time-restricted Eating and Circadian Dysregulation, sponsored by Salk Institute for Biological Studies.

NCT07203196 is a NA study of Time-restricted Eating and Circadian Dysregulation that is active but no longer recruiting, run by Salk Institute for Biological Studies. The registered enrollment target is 16 participants, below the 115-participant average among 12 other Time-restricted Eating trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07203196, a NA study of Time-restricted Eating and Circadian Dysregulation, is active but no longer recruiting, sponsored by Salk Institute for Biological Studies.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
16 participants
Enrollment target
1
Study location

Study Summary

In this single arm intervention trial, the investigators will assess the impact of a personalized lifestyle plan, centered on supporting biological rhythms, on blood sugar levels, physical, cognitive and immune function in older adults with a habitual eating window of 12 hours or more, and elevated blood glucose levels. All participants will be provided with a personalized circadian rhythm optimization plan (CRO) centered on improving (1) diet, (2) exercise (3) sleep habits based on their body's natural rhythms. The study includes a 2-week screening/baseline assessments, with follow-up health assessments at 2-months.

Primary Outcome

HbA1c levels (%) as assessed by fasting blood draw

Interventions

  • BEHAVIORAL Circadian Rhythm Optimization

Study Locations (1)

California

  • University of California San Diego - La Jolla

Trial Details

FieldValue
Enrollment Target 16 participants
Start Date 2025-10-22
Est. Completion 2026-04-01
Phase NA

What the registry record for NCT07203196 still lists

NCT07203196 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 115-participant average among 12 other Time-restricted Eating trials with a reported enrollment target (86% lower).

The record links to 5 conditions, with Time-restricted Eating appearing as the primary indexed condition, and to 1 intervention - of which Circadian Rhythm Optimization is the first listed.

NCT07203196 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT07203196 about?

NCT07203196 is a clinical study titled "Circadian Health Regulation and Optimization for Rejuvenation Outcomes". In this single arm intervention trial, the investigators will assess the impact of a personalized lifestyle plan, centered on supporting biological rhythms, on blood sugar levels, physical, cognitive and immune function in older adults with a habitual eating window of 12 hours or more, and elevated ...

What is the current status of trial NCT07203196?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 16 participants. The study started on 2025-10-22. Estimated completion is 2026-04-01.

What conditions does trial NCT07203196 study?

This clinical trial studies the following conditions: Time-restricted Eating, Circadian Dysregulation, Blood Sugar; High, Aging, Healthy, Blood Sugar (Glucose) Control.

What interventions are being tested in trial NCT07203196?

The interventions under investigation include: Circadian Rhythm Optimization (BEHAVIORAL).

Who is sponsoring clinical trial NCT07203196?

This trial is sponsored by Salk Institute for Biological Studies, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07203196 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Time-restricted Eating

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07203196's enrollment target sits among peer trials

16 12th of 12 higher than 1 of 12 other Time-restricted Eating trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Time-restricted Eating trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02422641 · 16 participants · Phase 2

    Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis

  • NCT02851758 · 16 participants · NA

    Transplantation of Autologously Derived Mitochondria Following Ischemia

  • NCT03291028 · 16 participants

    Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma

  • NCT03425526 · 16 participants · Phase 1

    Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07203196, the US trial registry maintained by the National Library of Medicine. NCT07203196 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.